# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

> **NCT03155503** · PHASE1 · COMPLETED · sponsor: **Suven Life Sciences Limited** · enrollment: 64 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** SUVN-911
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03155503
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-03-14
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03155503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03155503, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03155503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*